Learn more about how to participate in the study and where the miR-AGE study will be conducted.
Have you already tested positive for Covid-19? or
Do you have one of Covid-19 related typical symptoms such as fever, cough or shortness of breath and are planning to get tested for Covid-19?
If you already tested positive or will be tested positive for Covid-19, you might be eligible toparticipate in the study if you fall under one of the criteria below:
(defined as BMI ≥ 30)
Recent history of uncontrolled High Blood Pressure (SBP > 150 mm Hg DBP >100 mm Hg)
.svg)
Treated diabetes (type I or II)
History of ischemic cardiovascular disease
Older than 65 years
If your Covid-19 test is positive and you meet one of the above criteria you can go to one of the hospitals where the trial is conducted in order to evaluate your eligibility to participate in the study and to get more information.
To see the list of study centers where the trial is conducted, please change to the Portuguese and Spanish website versions.
Abivax is a biotechnology company based in France, founded in 2013 and listed on the Paris Stock Exchange since 2015. Abivax mobilizes the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464), COVID-19 (ABX464), HIV (ABX464), and liver cancer (ABX196). Abivax’s mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Dr. Jorge Kalil
Professor at FMUSP
miR-AGE Trial National Coordinator
CRM-SP 52834
.svg)
.svg)
